NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $219.47
  • Forecasted Upside: 48.04 %
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 14 Buy Ratings
  • 0 Strong Buy Ratings
▲ +2.4 (1.65%)

This chart shows the closing price for ALNY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alnylam Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALNY

Analyst Price Target is $219.47
▲ +48.04% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Alnylam Pharmaceuticals in the last 3 months. The average price target is $219.47, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 48.04% upside from the last price of $148.25.

This chart shows the closing price for ALNY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 18 investment analysts is to buy stock in Alnylam Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/27/2022GuggenheimDowngradeBuy ➝ NeutralLow
6/16/2022Needham & Company LLCInitiated CoverageBuy$205.00High
6/15/2022SVB LeerinkBoost Price TargetMarket Perform$96.00 ➝ $98.00High
6/7/2022William BlairInitiated CoverageOutperformMedium
5/2/2022HC WainwrightBoost Price Target$400.00 ➝ $430.00Medium
4/29/2022CitigroupLower Price Target$223.00 ➝ $211.00High
4/25/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$210.00 ➝ $178.00Medium
4/12/2022HC WainwrightBoost Price TargetBuy$350.00 ➝ $400.00Medium
4/6/2022OppenheimerReiterated RatingOutperform$205.00Low
3/24/2022Stifel NicolausReiterated RatingBuy$215.00Low
2/28/2022CitigroupInitiated CoverageBuy$223.00High
2/23/2022Morgan StanleyLower Price TargetOverweight$215.00 ➝ $210.00Low
2/11/2022Chardan CapitalReiterated RatingBuy$200.00Medium
2/11/2022SVB LeerinkLower Price TargetMarket Perform$109.00 ➝ $103.00Medium
2/3/2022GuggenheimUpgradeNeutral ➝ Buy$170.00Low
1/28/2022SVB LeerinkBoost Price TargetMarket Perform$108.00 ➝ $109.00High
1/20/2022HC WainwrightBoost Price TargetBuy$250.00 ➝ $350.00High
1/18/2022Morgan StanleyLower Price TargetOverweight$226.00 ➝ $215.00High
1/3/2022Bank of AmericaReiterated RatingBuy ➝ Buy$211.00Medium
1/3/2022Piper SandlerUpgradeNeutral ➝ Overweight$181.00 ➝ $208.00Low
12/30/2021OppenheimerReiterated RatingOutperform$200.00Low
12/1/2021SVB LeerinkReiterated RatingHoldMedium
11/22/2021Needham & Company LLCBoost Price TargetBuy$180.00 ➝ $205.00High
11/22/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy$273.00High
11/22/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$144.00 ➝ $225.00High
11/1/2021OppenheimerUpgradeMarket Perform ➝ Outperform$200.00Low
10/31/2021BMO Capital MarketsReiterated RatingHold ➝ NeutralMedium
10/29/2021Morgan StanleyLower Price TargetOverweight$242.00 ➝ $226.00High
10/29/2021Chardan CapitalBoost Price TargetBuy$190.00 ➝ $200.00High
10/29/2021Cantor FitzgeraldBoost Price TargetOverweight$202.00 ➝ $275.00Low
10/28/2021SVB LeerinkBoost Price TargetMarket Perform$104.00 ➝ $108.00High
10/18/2021SVB LeerinkReiterated RatingMarket PerformLow
10/12/2021Morgan StanleyBoost Price TargetOverweight$234.00 ➝ $242.00Low
10/4/2021UBS GroupUpgradeNeutral ➝ Buy$141.00 ➝ $215.00Low
8/27/2021BMO Capital MarketsBoost Price TargetNeutral ➝ Market Perform$174.00 ➝ $196.00Medium
8/13/2021HC WainwrightBoost Price TargetBuy$235.00 ➝ $250.00High
8/4/2021Chardan CapitalReiterated RatingBuy$190.00Medium
8/4/2021Morgan StanleyBoost Price TargetOverweight$224.00 ➝ $234.00High
8/4/2021BarclaysBoost Price TargetOverweight$196.00 ➝ $216.00High
8/4/2021Piper SandlerDowngradeOverweight ➝ Neutral$45.00 ➝ $47.00High
7/16/2021Morgan StanleyBoost Price TargetOverweight$205.00 ➝ $224.00High
4/30/2021Morgan StanleyLower Price TargetOverweight$206.00 ➝ $205.00Low
4/20/2021Needham & Company LLCReiterated RatingBuyLow
3/1/2021GuggenheimReiterated RatingBuy ➝ Neutral$162.00Low
2/22/2021GuggenheimDowngradeBuy ➝ Neutral$162.00Medium
2/14/2021Royal Bank of CanadaReiterated RatingHoldLow
2/12/2021Needham & Company LLCBoost Price TargetBuy$160.00 ➝ $180.00Low
2/12/2021Morgan StanleyBoost Price TargetOverweight$203.00 ➝ $206.00Low
2/12/2021CitigroupDowngradeBuy ➝ Neutral$170.00 ➝ $175.00Low
2/12/2021BarclaysBoost Price TargetOverweight$162.00 ➝ $196.00Low
2/12/2021HC WainwrightBoost Price TargetBuy$225.00 ➝ $235.00Low
1/25/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$185.00 ➝ $185.00High
1/13/2021CowenBoost Price TargetIn-Line ➝ Outperform$154.00 ➝ $197.00High
1/8/2021HC WainwrightReiterated RatingBuy$225.00High
12/21/2020Royal Bank of CanadaLower Price TargetSector Perform$150.00 ➝ $144.00Medium
12/17/2020Piper SandlerBoost Price TargetOverweight$169.00 ➝ $181.00Low
11/25/2020BMO Capital MarketsBoost Price Target$182.00 ➝ $183.00Low
11/25/2020Morgan StanleyBoost Price TargetOverweight$200.00 ➝ $203.00Low
11/24/2020SVB LeerinkBoost Price TargetMarket Perform$90.00 ➝ $91.00Low
11/6/2020Morgan StanleyBoost Price TargetOverweight$197.00 ➝ $200.00High
10/15/2020Bank of AmericaLower Price TargetBuy$160.00 ➝ $157.00Low
10/12/2020Chardan CapitalReiterated RatingBuyLow
9/30/2020OppenheimerReiterated RatingHold$156.00Medium
9/30/2020Berenberg BankInitiated CoverageHold$145.00Medium
9/8/2020CitigroupInitiated CoverageBuy$170.00 ➝ $170.00Low
8/24/2020HC WainwrightReiterated RatingBuyLow
8/11/2020OppenheimerDowngradeOutperform ➝ Market Perform$162.00 ➝ $156.00Low
8/7/2020Morgan StanleyLower Price TargetOverweight$199.00 ➝ $197.00Low
8/7/2020Chardan CapitalReiterated RatingBuyLow
8/7/2020SVB LeerinkBoost Price TargetMarket Perform$89.00 ➝ $90.00Low
7/20/2020BMO Capital MarketsBoost Price TargetOutperform$173.00 ➝ $196.00High
7/15/2020Morgan StanleyBoost Price TargetOverweight$162.00 ➝ $199.00Low
5/28/2020UBS GroupBoost Price TargetNeutral$111.00 ➝ $122.00Low
5/12/2020Royal Bank of CanadaInitiated CoverageSector Perform$150.00Medium
5/7/2020BMO Capital MarketsBoost Price TargetOutperform$145.00 ➝ $171.00Low
5/7/2020OppenheimerBoost Price TargetOutperform$140.00 ➝ $162.00High
5/7/2020Morgan StanleyBoost Price TargetOverweight$148.00 ➝ $162.00High
5/7/2020BarclaysBoost Price TargetOverweight$143.00 ➝ $156.00High
5/7/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$133.00 ➝ $137.00High
5/6/2020Needham & Company LLCBoost Price TargetBuy$135.00 ➝ $160.00High
4/24/2020Evercore ISIInitiated CoverageBuy$160.00Low
4/14/2020Needham & Company LLCReiterated RatingBuy$135.00High
4/14/2020Cantor FitzgeraldBoost Price Target$195.00 ➝ $202.00Low
4/14/2020Piper SandlerLower Price Target$147.00 ➝ $142.00Medium
4/14/2020Nomura SecuritiesLower Price TargetReduce$75.00 ➝ $74.00Medium
4/13/2020OppenheimerReiterated RatingBuy$140.00Medium
3/19/2020Berenberg BankInitiated CoverageBuy$200.00Low
3/5/2020CowenReiterated RatingBuyMedium
3/3/2020Piper SandlerReiterated RatingBuy$155.00N/A
2/11/2020Nomura SecuritiesBoost Price TargetReduce$62.00 ➝ $75.00Medium
2/9/2020CowenReiterated RatingBuy$154.00High
2/7/2020Evercore ISIInitiated CoverageBuy$145.00High
2/7/2020Morgan StanleyLower Price TargetOverweight$150.00 ➝ $148.00Medium
2/7/2020Chardan CapitalReiterated RatingBuyHigh
2/7/2020Needham & Company LLCReiterated RatingBuyHigh
12/19/2019Chardan CapitalBoost Price TargetBuy$150.00 ➝ $190.00Low
12/18/2019Nomura SecuritiesReiterated RatingSell$62.00Low
12/18/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$159.00 ➝ $176.00Medium
12/17/2019Piper Jaffray CompaniesBoost Price TargetOverweight$145.00 ➝ $155.00Medium
12/17/2019Morgan StanleyBoost Price TargetOverweight$141.00 ➝ $150.00High
11/27/2019Cantor FitzgeraldBoost Price Target$150.00 ➝ $159.00Low
11/21/2019BMO Capital MarketsBoost Price TargetOutperform$128.00 ➝ $138.00High
11/21/2019BarclaysBoost Price TargetOverweight$125.00 ➝ $131.00High
11/21/2019Needham & Company LLCInitiated CoverageBuy$135.00Low
11/21/2019Cantor FitzgeraldReiterated RatingBuy$150.00 ➝ $159.00Low
11/19/2019OppenheimerInitiated CoverageOutperform$128.00 ➝ $128.00High
11/18/2019CowenReiterated RatingBuy$120.00High
11/13/2019Bank of AmericaInitiated CoverageBuy$110.00Low
10/31/2019Needham & Company LLCReiterated RatingBuy$135.00Low
10/8/2019Nomura SecuritiesSet Price TargetSell$62.00Low
9/10/2019Piper Jaffray CompaniesSet Price TargetBuy$145.00High
9/4/2019UBS GroupBoost Price TargetNeutral$95.00 ➝ $96.00Low
9/3/2019Stifel NicolausSet Price TargetBuy$116.00Low
9/3/2019Piper Jaffray CompaniesBoost Price TargetOverweight$142.00 ➝ $145.00Medium
8/26/2019Piper Jaffray CompaniesSet Price TargetBuy$142.00Low
8/7/2019BarclaysReiterated RatingBuy$125.00High
8/7/2019Morgan StanleyLower Price TargetOverweight$126.00 ➝ $124.00High
8/7/2019CowenLower Price TargetOutperform$147.00 ➝ $120.00High
5/23/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$80.00Medium
5/2/2019Morgan StanleySet Price TargetBuy$126.00High
5/2/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$126.00 ➝ $128.00High
4/15/2019Stifel NicolausBoost Price TargetBuy ➝ Buy$110.00 ➝ $116.00Low
4/15/2019Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$135.00 ➝ $138.00Low
4/15/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$119.00 ➝ $126.00Low
4/11/2019Evercore ISIInitiated CoverageOutperform$120.00Medium
4/9/2019SVB LeerinkBoost Price TargetMarket Perform$90.00Medium
4/9/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$106.00 ➝ $119.00High
4/9/2019Cantor FitzgeraldReiterated RatingBuy$135.00Medium
4/9/2019Chardan CapitalReiterated RatingBuy$150.00Medium
3/6/2019CowenReiterated RatingBuyLow
3/6/2019Evercore ISIUpgradeIn-Line ➝ OutperformLow
3/5/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$122.00Low
2/8/2019Needham & Company LLCReiterated RatingBuy$135.00High
2/8/2019BMO Capital MarketsLower Price TargetOutperform$106.00High
2/7/2019Cantor FitzgeraldReiterated RatingBuy$135.00High
1/23/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$87.00Low
1/15/2019Piper Jaffray CompaniesLower Price TargetOverweight$152.00Low
12/17/2018GuggenheimInitiated CoverageBuy$105.00Medium
12/7/2018Cantor FitzgeraldReiterated RatingBuy$135.00High
11/27/2018SVB LeerinkInitiated CoverageMarket Perform$63.00Low
11/8/2018Cantor FitzgeraldReiterated RatingBuyN/A
10/18/2018BMO Capital MarketsReiterated RatingBuyHigh
10/16/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$125.00 ➝ $124.00Medium
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$135.00Low
9/28/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$93.00 ➝ $87.00High
9/13/2018Needham & Company LLCReiterated RatingBuy$152.00Medium
9/13/2018Stifel NicolausReiterated RatingBuy$123.00 ➝ $117.00Medium
9/4/2018CowenReiterated RatingBuy$147.00High
8/28/2018JMP SecuritiesSet Price TargetBuy$198.00Medium
8/27/2018Needham & Company LLCSet Price TargetBuy$152.00Low
8/13/2018B. RileyBoost Price TargetBuy ➝ Buy$210.00 ➝ $230.00High
8/13/2018Nomura SecuritiesLower Price TargetReduce ➝ Reduce$86.00 ➝ $73.00High
8/13/2018Morgan StanleySet Price TargetEqual Weight ➝ Hold$99.00 ➝ $93.00High
8/13/2018Needham & Company LLCReiterated RatingBuy$152.00High
8/13/2018CowenLower Price TargetOutperform ➝ Outperform$157.00 ➝ $147.00High
8/13/2018Stifel NicolausReiterated RatingSell ➝ Buy$125.00 ➝ $123.00Medium
8/13/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyLow
8/13/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$127.00 ➝ $125.00High
8/6/2018Stifel NicolausUpgradeHold ➝ Buy$95.00 ➝ $125.00Low
8/6/2018Jefferies Financial GroupReiterated RatingBuy$149.00Low
8/6/2018JMP SecuritiesSet Price TargetBuy$207.00Medium
8/3/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$107.00 ➝ $99.00High
8/3/2018Chardan CapitalReiterated RatingBuy$180.00High
8/3/2018BMO Capital MarketsReiterated RatingBuy$127.00High
8/2/2018CowenReiterated RatingBuy$157.00High
7/23/2018Piper Jaffray CompaniesReiterated RatingOverweightLow
6/27/2018Piper Jaffray CompaniesLower Price TargetOverweight$182.00 ➝ $160.00Medium
5/7/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$118.00Medium
5/4/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$160.00 ➝ $134.00N/A
5/4/2018Stifel NicolausLower Price TargetHold ➝ Hold$107.00 ➝ $95.00High
4/2/2018B. RileyReiterated RatingBuy$200.00Medium
4/2/2018Jefferies Financial GroupReiterated RatingBuyHigh
3/28/2018Evercore ISIInitiated CoverageIn ➝ line$131.18 ➝ $143.00Medium
3/26/2018JMP SecuritiesBoost Price TargetMkt Outperform ➝ Outperform$169.00 ➝ $207.00Low
3/13/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$151.00 ➝ $154.00High
2/16/2018B. RileyLower Price TargetBuy ➝ Buy$205.00 ➝ $200.00Medium
2/9/2018Credit Suisse GroupSet Price TargetBuy$151.00Low
2/9/2018Jefferies Financial GroupSet Price TargetBuy$156.00Low
2/9/2018Nomura SecuritiesBoost Price TargetSell$86.00Low
2/9/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$165.00 ➝ $160.00Medium
2/9/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$128.00 ➝ $118.00Medium
1/25/2018SVB LeerinkBoost Price TargetMarket Perform ➝ Market Perform$132.00 ➝ $135.00Low
1/19/2018B. RileyReiterated RatingBuy$205.00Low
1/19/2018Chardan CapitalReiterated RatingBuyLow
1/8/2018B. RileyReiterated RatingBuy ➝ Buy$220.00 ➝ $205.00Medium
1/7/2018Piper Jaffray CompaniesReiterated RatingBuy$182.00Medium
12/15/2017The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyHigh
12/11/2017B. RileyReiterated RatingBuy$220.00Low
11/17/2017Piper Jaffray CompaniesReiterated RatingBuy$182.00N/A
11/9/2017CowenReiterated RatingBuy$151.00N/A
11/9/2017Morgan StanleyBoost Price TargetEqual Weight$101.00 ➝ $130.00N/A
11/9/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightN/A
11/8/2017B. RileyLower Price TargetBuy$220.00N/A
11/8/2017BarclaysBoost Price TargetOverweight$127.00 ➝ $158.00N/A
11/3/2017Credit Suisse GroupBoost Price TargetOutperform$123.00 ➝ $151.00N/A
11/3/2017CowenReiterated RatingOutperform$117.00 ➝ $151.00N/A
11/3/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$125.00 ➝ $152.00N/A
11/2/2017Piper Jaffray CompaniesReiterated RatingOverweight$188.00 ➝ $14.71N/A
11/1/2017B. RileyInitiated CoverageBuy$150.00 ➝ $240.00N/A
10/30/2017FBR & Co.Initiated CoverageBuy ➝ Buy$150.00N/A
10/2/2017The Goldman Sachs GroupUpgradeNeutral ➝ Buy$62.00 ➝ $163.00Medium
9/26/2017Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$102.00 ➝ $130.00Low
9/25/2017Chardan CapitalReiterated RatingBuy$124.00Low
9/22/2017BMO Capital MarketsReiterated RatingOutperform$99.00 ➝ $134.00Low
9/21/2017LADENBURG THALM/SH SHReiterated RatingBuy$90.00 ➝ $146.00Low
9/21/2017Sanford C. BernsteinReiterated RatingOutperform ➝ Buy$94.00 ➝ $135.00Low
9/20/2017Stifel NicolausReiterated RatingHold$56.00 ➝ $83.00Low
9/20/2017CowenReiterated RatingOutperform$93.00 ➝ $117.00Low
9/20/2017Piper Jaffray CompaniesReiterated RatingOverweight$110.00 ➝ $116.00Low
9/20/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$85.00 ➝ $125.00Low
9/20/2017JMP SecuritiesBoost Price TargetOutperform$101.00 ➝ $128.00Low
9/18/2017Jefferies Financial GroupReiterated RatingBuy$102.00Low
9/15/2017Nomura InstinetInitiated CoverageReduce ➝ Reduce$56.00Low
9/14/2017Nomura SecuritiesInitiated CoverageReduce$56.00High
9/11/2017Chardan CapitalReiterated RatingBuyHigh
9/8/2017SVB LeerinkReiterated RatingMarket Perform$83.00 ➝ $72.00Low
9/7/2017Piper Jaffray CompaniesReiterated RatingOverweight$126.00 ➝ $110.00Low
9/7/2017Needham & Company LLCReiterated RatingBuy$98.00 ➝ $85.00Low
9/7/2017BarclaysReiterated RatingEqual Weight ➝ Overweight$80.00 ➝ $105.00High
9/6/2017BMO Capital MarketsReiterated RatingOutperform$105.00 ➝ $99.00Low
8/25/2017Jefferies Financial GroupSet Price TargetBuy$102.00Low
8/11/2017Credit Suisse GroupReiterated RatingBuy$96.00Low
8/10/2017Stifel NicolausReiterated RatingBuy$47.00 ➝ $56.00Medium
8/10/2017Chardan CapitalReiterated RatingBuy$131.00 ➝ $124.00Medium
8/10/2017Morgan StanleyBoost Price TargetEqual Weight$46.00 ➝ $50.00Medium
8/10/2017BarclaysBoost Price TargetEqual Weight$50.00 ➝ $70.00High
7/27/2017Sanford C. BernsteinInitiated CoverageOutperform$99.00High
7/17/2017LADENBURG THALM/SH SHSet Price TargetBuy ➝ Buy$80.00 ➝ $90.00Low
7/11/2017CowenReiterated RatingBuy$100.00Low
7/11/2017Credit Suisse GroupSet Price TargetBuy$96.00Low
7/10/2017Morgan StanleyReiterated RatingEqual WeightLow
7/10/2017Needham & Company LLCReiterated RatingBuy$98.00Low
7/10/2017Chardan CapitalReiterated RatingBuy$110.00 ➝ $131.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 7 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
  • 0 very positive mentions
  • 7 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 4 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $148.25
Low: $144.67
High: $148.40

50 Day Range

MA: $134.91
Low: $120.42
High: $155.00

52 Week Range

Now: $148.25
Low: $117.58
High: $212.00


29,478 shs

Average Volume

978,264 shs

Market Capitalization

$17.91 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Alnylam Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Alnylam Pharmaceuticals in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Guggenheim, HC Wainwright, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Stifel Nicolaus,, SVB Leerink LLC, The Goldman Sachs Group, Inc., UBS Group AG, and William Blair.
View the latest analyst ratings for ALNY.

What is the current price target for Alnylam Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Alnylam Pharmaceuticals in the last year. Their average twelve-month price target is $219.47, suggesting a possible upside of 48.0%.
View the latest price targets for ALNY.

What is the current consensus analyst rating for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals currently has 4 hold ratings and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALNY will outperform the market and that investors should add to their positions of Alnylam Pharmaceuticals.
View the latest ratings for ALNY.

How do I contact Alnylam Pharmaceuticals' investor relations team?

Alnylam Pharmaceuticals' physical mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is (617) 551-8200 and its investor relations email address is [email protected] The official website for Alnylam Pharmaceuticals is Learn More about contacing Alnylam Pharmaceuticals investor relations.